LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 UNITED STATES DISTRICT COURT

EASTERN DISTRICT OF MICHIGAN

SOUTHERN DIVISION

KRISTEN HUSBY, Individually

and on behalf of all others similarly situated,

and MICHAEL HUSBY, Individually,

Case No.

Plaintiffs, Hon.

v.

IOVATE HEALTH SCIENCES USA, INC.,

IOVATE HEALTH SCIENCES INTERNATIONAL, INC.,

IOVATE HEALTH SCIENCES GROUP, INC.,

IOVATE HEALTH SCIENCES RESEARCH, INC.,

IOVATE HC 2005 FORMULATIONS LTD., 

MUSCLETECH, INC., MUSCLETECH,

MUSCLETECH RESEARCH AND DEVELOPMENT, INC.,

Jointly and Severally,

Defendants.

_________________________________________________/

SOMMERS SCHWARTZ, P.C.

Jason J. Thompson (P47184)

Robert H. Darling (P25523)

Matthew G. Curtis (P37999)

Attorneys for Plaintiffs

2000 Town Center, Ste. 900

Southfield, MI 48075

(248) 355-0300

_________________________________________________/

COMPLAINT AND DEMAND FOR TRIAL BY JURY

Husby et al v. Iovate Health Sciences USA, Inc. et al Doc. 1

Dockets.Justia.com
 

i LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 TABLE OF CONTENTS

NATURE OF THE CASE........................................................................................................................... 2

PARTIES..................................................................................................................................................... 2

JURISDICTION AND VENUE ................................................................................................................. 4

FACTUAL ALLEGATIONS...................................................................................................................... 4

I. Obesity and Diet Supplements............................................................................................ 4

II. Hydroxycut.......................................................................................................................... 5

III. Reports of Hydroxycut-Related Injuries............................................................................. 6

IV. FDA Writes Iovate on April 30, 2009............................................................................... 10

V. FDA Hydroxycut Warnings.............................................................................................. 12

VI. Hydroxycut Products are Recalled.................................................................................... 17

VII. Plaintiff s Experience........................................................................................................ 21

CLASS ACTION ALLEGATIONS.......................................................................................................... 22

TOLLING OF APPLICABLE STATUTE OF LIMITATIONS .............................................................. 25

COUNT I - PRODUCT LIABILITY ACTION........................................................................................ 25

COUNT II - PRODUCT LIABILITY ACTION WARNING ............................................................... 26

COUNT III - BREACH OF EXPRESSED WARRANTY....................................................................... 28

COUNT IV - NEGLIGENCE ................................................................................................................... 29

COUNT V - GROSS NEGLIGENCE....................................................................................................... 31

COUNT VI - RECKLESSNESS............................................................................................................... 31

COUNT VII - BREACH OF IMPLIED WARRANTY............................................................................ 32

COUNT VIII - FRAUD AND MISREPRESENTATION........................................................................ 32

COUNT IX - MICHIGAN CONSUMERS PROTECTION ACT............................................................ 33

DEMAND FOR JURY TRIAL................................................................................................................. 35
 1

LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 UNITED STATES DISTRICT COURT

EASTERN DISTRICT OF MICHIGAN

SOUTHERN DIVISION

KRISTEN HUSBY, Individually

and on behalf of all others similarly situated,

and MICHAEL HUSBY, Individually,

Case No.

Plaintiffs, Hon.

v.

IOVATE HEALTH SCIENCES USA, INC.,

IOVATE HEALTH SCIENCES INTERNATIONAL, INC.,

IOVATE HEALTH SCIENCES GROUP, INC.,

IOVATE HEALTH SCIENCES RESEARCH, INC.,

IOVATE HC 2005 FORMULATIONS LTD., 

MUSCLETECH, INC., MUSCLETECH,

MUSCLETECH RESEARCH AND DEVELOPMENT, INC.,

Jointly and Severally,

Defendants.

_________________________________________________/

SOMMERS SCHWARTZ, P.C.

Jason J. Thompson (P47184)

Robert H. Darling (P25523)

Matthew G. Curtis (P37999)

Attorneys for Plaintiffs

2000 Town Center, Ste. 900

Southfield, MI 48075

(248) 355-0300

_________________________________________________/

COMPLAINT AND DEMAND FOR TRIAL BY JURY

NOW COME the Plaintiffs Kristen and Michael Husby, by and through their attorneys

SOMMERS SCHWARTZ, P.C. and for their complaint against Iovate Health Sciences USA, Inc., Iovate Health Sciences International, Inc., Iovate Health Sciences Group, Inc., Iovate Health Sciences

Research, Inc., Iovate HC 2005 Formulations Ltd., Muscletech, Inc., Muscletech, Muscletech Research
 2 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

and Development, Inc., Jointly and Severally (collectively hereinafter Product Defendants ) states as

follows:

NATURE OF THE CASE

1. This putative class action seeks damages suffered by Plaintiffs Kristen and Michael

Husby as a direct and proximate result of the wrongful conduct of the Product Defendants in connection

with the design, testing, quality assurance, manufacturing, labeling, warning, packaging, marketing, advertising, promotion, supply, distribution, post-market monitoring and/or surveillance, sale, and recall

of its Hydroxycut weight loss products ( Hydroxycut Products ). PARTIES

2. Plaintiffs Kristen and Michael Husby, husband and wife (hereinafter Plaintiff or

Plaintiffs ) are and were at all times relevant hereto residents of the City of Livonia, State of Michigan. Plaintiff used Hydroxycut Products manufactured by the Product Defendants which gave rise to severe

injuries. As a direct and proximate result of using Hydroxycut Products, Plaintiff Kristen Husby

suffered liver injuries resultant in the injuries and damages set forth herein.

3. Iovate Health Sciences USA, Inc. is a foreign corporation with its principle place of

business at 3880 Jeffrey Blvd., Buffalo, NY 14219. 4. Iovate Health Sciences International, Inc. is a foreign corporation with its principle place 

of business located at 381 North Service Road West, Oakville, Ontario, Canada L6M-0H4. 5. Iovate Health Sciences Group, Inc. is a foreign corporation with its principle place of

business at 381 North Service Road West, Oakville, Ontario, Canada L6M-0H4.

6. Iovate Health Sciences Research, Inc. is a foreign corporation with its principle place of

business located at 381 North Service Road West, Oakville, Ontario, Canada L6M-0H4.
 3 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

7. Iovate HC 2005 Formulations Ltd. is a foreign corporation with its principle place of

business located at 381 North Service Road West, Oakville, Ontario, Canada L6M-0H4.

8. Muscletech, Inc. is a foreign corporation with its principle place of business located at

2422 Broadway, Suite B, Lubick, TX 79401.

9. Muscletech is a foreign corporation with its principle place of business located at 1785 S. Park Avenue, Buffalo, NY 14220.

10. Muscletech Research and Development, Inc. is a foreign corporation with its principle

place of business located at 7050 Telford Way, Mississauga, Ontario, Canada L5S-1B7.

11. The above mentioned companies (hereinafter Product Defendants ) are named as

Defendants herein.

12. Plaintiff is informed and believes, and thereon alleges, that at all times herein mentioned, that the employees of Product Defendants, their subsidiaries, affiliates and other related entities, were

the agents, servants, and employees of the Product Defendants and at all times herein mentioned, each

was acting within the purpose of scope of said agency and employment. Whenever reference in this

complaint is made to any act or transaction of any defendant, such allegation shall be deemed to mean

that the principals, officers, directors, employees, agents, and/or other representatives of said Product

Defendants committed, knew of, performed, authorized, ratified, and/or directed such act or transaction

on behalf of said Product Defendants while actively engaged in the scope of their duties. 
 4 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

JURISDICTION AND VENUE

13. This Court has diversity subject matter jurisdiction over this class action pursuant to 28

U.S.C. § 1332(d) in that this is a civil action filed under Rule 23 of the Federal Rules of Civil Procedure

and members of the class of plaintiffs are citizens of a State different from the Product Defendants, and

the aggregated amount in controversy exceeds $5,000,000, exclusive of interest and costs. See 28 U.S.C. 

§ 1332(d)(2), (6).

14. Venue in this judicial district is proper pursuant to 28 U.S.C. §1331 because the 

substantial part of the events or omissions giving rise to the claim occurred in this district.

FACTUAL ALLEGATIONS

15. The Product Defendants are in the business of formulating, designing, manufacturing, marketing, and advertising, distributing and selling various dietary supplements including muscle

builders and fat burners/thermogenics. 

16. Said products are sold with the stores throughout the United States. 

17. In 2008, at least 9 million packages of Hydroxycut Products were sold in this country.

I. Obesity and Diet Supplements

18. Obesity has become an increasingly important public health problem in the United States. 

Recent data show that more than 30% of adults are obese and 65% overweight. 

19. The use of dietary supplements for weight loss has become increasingly popular, as

reflected by the $55.4 billion spent in United States in 2006 for weight loss and diet control. Based on a 

study by the National Center for Complimentary and Alternative Medicine (NCCAM), 36% of adults
 5 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

are using some form of complimentary or alternative medicine, which rises to 62% when including

megavitamins or prayer. 

20. Although dietary and herbal supplements are governed under the DSHEA (Dietary

Supplements Health and Education Act) of 1994, they are not presently regulated by the US Federal

Drug Administration, and the safety profiles of many are unknown. 

II. Hydroxycut

21. Hydroxycut is the brand name of some of America s top-selling weight-loss products

which are taken by millions of consumers each year. Hydroxycut products are made by Iovate Health

Sciences of Oakville, Ontario, which has over 750 items sold in more than 70 countries around the

world. 

22. Hydroxycut is a Registered Trademark and is part of the name of many products, examples of which include Hydroxycut, Hydroxycut Hardcore, and Hydroxycut Caffeine Free. Iovate

and Muscletech, a company owned by Iovate, both market Hydroxycut products.

23. Hydroxycut has been marketed by Iovate Health Sciences, Inc (381 North Service Rd. W., Oakville, ON L6M 0H4, Canada) and manufactured by Muscletech (Blassdell, NY, USA and

Mississauga, Ontario, Canada) as a weight control, fat-burner, and energy enhancement dietary

supplement. Hydroxycut products bear the Iovate or Muscletech Brand names. In the United States, Hydroxycut products are distributed by Iovate Health Sciences USA, Inc., of Blasdell, New York.

24. The products contain a variety of individual ingredients as well as numerous proprietary

blends such as Hydroxagen Plus, Hydroxy Tea, HydroxyTea CF, Hydroxycut Proprietary Blend, Max!

Liqui-Burn, Max! Weight-Loss Matrix, Hydroxycut Hardcore Proprietary Blend Proxyclene, Noreidrol

Intensity focus Blend, Lasidrate Delivery Blend, or Yohimbacore.
 6 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

III. Reports of Hydroxycut-Related Injuries

25. In 2002, the Center for Food Safety and Applied Nutrition s (CFSAN) adverse event

reporting system, CAERS, began receiving reports of liver-related illnesses in persons who reported

consuming the dietary supplement Hydroxycut capsules/caplets for periods ranging from as short as a

week to two (2) months. Since the earlier formulation of Hydroxycut contained ephedra, it was generally 

believed that the reports of liver injury associated with the use of the product were due either to ephedra

or a combination of the ingredients found in the product. However, following the removal of ephedra

from Hydroxycut capsules/caplets, CFSAN continued to receive reports of liver injury associated with

the use of Hydroxycut capsules/caplets. In addition, CFSAN became aware of reports of Hydroxycut- associated liver toxicity published in the peer-reviewed literature and received communications from

independent hepatologists regarding cases of liver toxicity associated with the use of the Hydroxycut

capsules/caplets. 

Hydroxycut-associated liver toxicity reports in CAERS. The FDA reports that to-date, 23 case reports of Hydroxycut-associated liver toxicity have been 

identified in CAERS for the period 2002 to the present. The number of reports, by event date, is listed 

below:

Year of event Number of reports

2002 4

2003 3

2004 6

2005 0

2006 1

2007 6

2008 3
 7 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

2009 0 

Total 23

26. For cases in which gender was known, 15 (65%) were female. Ages ranged from 20 years 

to 51 years (median = 29 years). Sixteen cases (70%) were hospitalized. The majority of cases reported

no underlying risk factors for liver disease (e.g., no history of viral hepatitis, no HIV infection, no

autoimmune diseases). Although the reports vary in detail, several reports describe work-ups that ruled

out infectious, autoimmune, and metabolic causes of liver disease. The severity of illness ranged from

asymptomatic elevations in serum bilirubin to acute liver failure (one patient received a liver transplant

in 2002, a second patient was reportedly waiting for a liver transplant in 2004) to one death. 

27. On March 24, 2009, CFSAN received information regarding the fatal case. The patient

was a 20-year-old male who presented to an emergency room on January 19, 2007 in liver failure and

hepatic encephalopathy. He was subsequently transferred to a liver transplant center where, in the

operating room, he was found to have necrosis of both the large and small intestines. Given these

findings, the procedure was aborted and the patient was returned to the intensive care unit. He died on

February 12, 2007.
 8 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 Reports of Hydroxycut-associated liver toxicity in the peer-reviewed literature. 28. The FDA indicates that it was aware of four published reports in the peer-reviewed 

literature that describe liver disease that occurred in six persons following the consumption of

Hydroxycut capsules/ caplets.1

29. The FDA reports that the aforementioned cases are consistent with the diagnosis of

idiosyncratic hepatotoxicity for a number of reasons: the temporal relationship between the consumption 

of Hydroxycut capsules/caplets and the development of acute liver injury in persons who had no history

of known liver disease; the exclusion of other causes of liver disease following extensive work-ups; the

resolution of liver injury upon discontinuation of Hydroxycut capsules/caplets; and the development of

liver injury is not dose dependent. Also apparent were two distinct patterns of liver injury: cholestatic

and necrotic. It is not unusual for a single herbal preparation to produce more than one type of

clinicopathologic liver injury. 

Discussions with hepatologists. 30. The FDA reported findings from discussions in March and April 2009 with hepatologists

Tse-Ling Fong, M.D. of the University of Southern California, and William Lee, M.D. of the University

of Texas Southwestern Medical Center, CFSAN has become aware of these physicians case series of

patients with severe liver disease associated with the use of Hydroxycut capsules/caplets. Two cases

 1

 Stevens T, Qadri A, Zein NN. Two patients with acute liver injury associated with use of the herbal 

weight-loss supplement Hydroxycut. Ann Intern Med 2005;142:477-8; Jones FJ, Andrews AH. Acute 

liver injury associated with the herbal supplement Hydroxycut in a soldier deployed to Iraq. Am J 

Gastroenterol 2007;102:2357; Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: A case series and 

review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008;14:6999- 7004; Shim M, Saab S. Severe hepatotoxicity due to Hydroxycut: a case report. Dig Dis Sci 2009 

Feb;54(2):406-8. Epub 2008 Jul 26.
 9 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

from this series, representing additional cases to the ones reported to CFSAN, underwent liver

transplantation following acute liver failure. 

Serious non-hepatic adverse events identified in the CAERS database or the literature. 31. The FDA confirmed that when the CAERS database was queried for other serious

adverse events associated with Hydroxycut, cases of seizures, rhabdomyolysis, and cardiovascular

disorders were identified. For example, from 2004 to 2008, the CAERS database received four case

reports describing consumers who experienced a seizure following ingestion of Hydroxycut. In one

instance, a 26-year-old consumer increased her daily intake of Hydroxycut from 2 to 4 caplets on

December 6, 2008. At 2 p.m. that day, following ingestion of the second serving of 2 caplets, the

consumer felt tired and lay down. She was found by another person to be having a seizure (shaking

and drooling). The consumer was taken to the emergency room where a physician told her to

discontinue using Hydroxycut. 

32. Furthermore, according to the FDA, the case report describing rhabdomyolysis involved

a 23-year-old male who had been consuming Hydroxycut on and off over an eight-month period in

2002. On the day of hospital admission, he had taken 2 tablets for energy prior to working out. He

reported feeling nausea, and then several hours later, he had severe shoulder pain and dark urine. He was 

diagnosed as having rhabdomyolysis on admission to the hospital. In addition to this CAERS report, CFSAN is aware of one case of Hydroxycut capsules/caplets-associated rhabdomyolysis reported in the

peer-reviewed literature. In this report, Dehoney and Wellen described an 18-year-old male who

experienced rhabdomyolysis after consuming Hydroxycut as per the product s instructions. During his

overnight hospitalization, he received 6 liters of fluid before discharge. 

33. The Agency also identified 46 reports in CAERS of Hydroxycut capsules/caplets- associated cardiovascular adverse events. These events ranged in severity from palpitations to a heart
 10 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

attack. Nineteen of these reports were received during or after 2004, a period when Hydroxycut s

formulation was believed to be free of ephedra.

34. Prior to 2004, Hydroxycut, contained ephedra or Ma Huang as an ingredient; however, by 

the beginning of 2004, Hydroxycut was ephedra-free. Subsequent to the removal of ephedra, Hydroxycut had undergone numerous formulation changes.

35. However, following the removal of ephedra from Hydroxycut, CFSAN continued to

receive reports of liver injury associated with the use of Hydroxycut. An increasing number of case

reports have emerged which suggest causative supplement-associated liver toxicity. Hydroxycut is an

herbal weight loss supplement that has been suspected to have possible liver toxicity.

IV. FDA Writes Iovate on April 30, 2009

36. On April 30, 2009 Stephen F. Sundlof, Director Center for Food Safety and Applied

Nutrition wrote to Mr. Terry Begley of Iovate Health Sciences, Inc. The letter confirmed that on March

31, 2009, the U.S. Food and Drug Administration (FDA or the Agency) informed Iovate during a

meeting of concerns that the Agency had about liver toxicity associated with the use of multiple versions 

of the dietary supplement Hydroxycut marketed under the Iovate and MuscleTech brand names. The

FDA s concerns were based on adverse events reported to FDA, case reports in the peer-reviewed 

literature, and in a case series described by hepatologists to FDA. The Agency advised Iovate that it had 

concluded that the ingestion of the dietary supplement Hydroxycut presents a severe potentially lifethreatening hazard to some users. 37. The FDA reported that it held a telephone conversation on April 29, 2009, between

outside counsel for Iovate Health Sciences, Inc., and Mr. Eric Blumberg, Deputy Chief Counsel, Litigation, Office of Chief Counsel, FDA, wherein the Agency explained its conclusions about the
 11 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

safety of Hydroxycut products and the additional actions that the FDA expected Iovate to take in

response to the serious public health hazards presented by the Hydroxycut dietary supplements.

38. The FDA concluded that three lines of evidence derived from multiple disparate sources 

suggest it is very likely that exposure to Hydroxycut capsules/caplets can cause idiosyncratic

hepatotoxicity. First, many of the subjects described in the adverse event reports to CAERS, in the peerreviewed literature, and in the case series described by hepatologists reported no history of liver disease

or risk factors for liver disease (e.g., alcohol consumption, previous viral infection, hereditary factors, etc.) prior to experiencing liver injury following the ingestion of Hydroxycut capsules/caplets. Second, in many subjects, thorough diagnostic evaluations performed in multiple settings ruled out a number of

known causes of liver disease, including viral hepatitis, autoimmune diseases, and metabolic/inherited

disorders. Third, prompt resolution of liver disease occurred in a number of patients following cessation

of Hydroxycut capsules/caplets ingestion. While some adverse event reports involved users who had

consumed more than the daily dosage recommended on the products' labeling, if these reports were

excluded from consideration, the remaining evidence demonstrates liver-related adverse effects

following exposure to Hydroxycut capsules/caplets. In addition to Hydroxycut capsules/caplets- associated liver-related adverse effects, CFSAN is aware of a number of CAERS reports that describe

seizures, rhabdomyolysis, and cardiovascular signs and symptoms. 

39. The FDA, based on the totality of evidence, concluded that the ingestion of the dietary

supplement, Hydroxycut, presents a severe potentially life-threatening hazard to some users. 

40. The FDA also disagreed with claims of Iovate that some Hyroxycut products were safe:

While the firm believes that the lack of reported adverse events associated with 

the use of the Hydroxycut shot product and the drink mixes is evidence that they are safe, 

FDA disagrees. The reports of acute liver injury in individuals who have consumed 

Hydroxycut capsules/caplets represent idosyncratic reactions, meaning that the injuries 

have occurred as a result of conditions peculiar to the affected individuals. As such, the 

incidence of injuries of this nature is unpredictable and may result from peculiar 
 12 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 metabolic interactions between one or more Hydroxycut ingredient and the host s

physiologic system. There are no data to indicate that the dose or duration of use of any 

particular Hydroxycut ingredient, or the gender, or any other identifiable trait of a 

Hydroxycut user predicts the risk of an adverse event. In light of this, and because the 

fact that the drink mixes and shot products share ingredients with products known to be 

associated with adverse events, and because it is unknown which ingredient(s) of 

Hydroxycut are responsible for producing the idiosyncratic reactions, we believe that the 

reasonable conclusion to be drawn is that these products present the same risks as the 

Hydroxycut capsules/caplets. 

41. Given the seriousness of the hazard presented by Hydroxycut, Iovate Health Sciences, Inc. voluntarily agreed to the following:

1. To cease distribution of all existing formulations of Hydroxycut.

2. To recall from the marketplace, to the consumer/user level, all existing formulations of 

Hydroxycut.

As we stated above, the ingestion of the dietary supplement Hydroxycut presents a severe 

potentially life-threatening hazard to some users. FDA considers the recalled products to be 

adulterated under section 402(f)(1)(A) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. § 

342(f)(1)(A)] (the Act) in that the dietary supplements present a significant or unreasonable risk 

of illness or injury under conditions of use recommended or suggested in labeling.

V. FDA Hydroxycut Warnings

42. On May 1, 2009, the FDA issued an advisory which stated, "Although the liver damage

appears to be relatively rare, FDA believes consumers should not be exposed to unnecessary risk". The

number of adverse event reports described by the FDA is small relative to the many millions of people

who have used Hydroxycut products over the 7 years referenced by the FDA. Iovate's own assessment

of the potential risk associated with the use of these products differs from that expressed by the agency. Every product marketed by Iovate is evaluated during its development for the safety of its individual

ingredients. Additionally, independent third-party experts from the leading independent scientific firm

specializing in ingredient assessment, toxicology and product safety for the nutritional and

pharmaceutical industry reviews the safety of Iovate's ingredients and formulas before products are
 13 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

introduced into the market place. Only after this the external review is completed does Iovate release a

formula.

43. The U. S. FDA is warning consumers (5/1/09) to immediately stop using Hydroxycut

products by Iovate Health Services, Inc. of Oakville, Ontario. Some Hydroxycut products are associated 

with a number of serious liver injuries. Iovate has agreed to immediately recall Hydroxycut products

from the US market.

44. The FDA issued dear doctor letter that stated as follows:

Dear Health Care Professional Colleague: 

We are alerting you about a dietary supplement product that we believe presents a serious public 

health risk. Hydroxycut products are distributed by Iovate Health Sciences Inc., Oakville, 

Ontario Canada and distributed by Iovate Health Sciences U.S.A., Inc. of Blasdell, NY, and have 

been implicated in several cases of serious liver injury. The Food and Drug Administration 

(FDA) has received 23 reports of adverse liver effects in users of Hydroxycut products, ranging 

from asymptomatic hyperbilirubinemia, jaundice, liver damage, liver transplant, and death. The 

injuries reported to FDA occurred in persons between 21 and 51 years of age. No other cause for 

liver disease was identified. In the majority of cases, no preexisting medical condition that would 

predispose the consumer to liver injury was identified. In some cases, discontinuation of 

Hydroxycut usage resulted in recovery of liver function. Although the liver damage appears to be 

relatively rare, FDA believes consumers should not be exposed to unnecessary risk. FDA has 

also identified several other serious adverse events associated with Hydroxycut, including cases 

of seizures, rhabdomyolysis, and cardiovascular disorders ranging in severity from palpitations 

to a heart attack.

Hydroxycut products bear the Iovate or Muscletech Brand name and are multi-ingredient dietary 

supplements marketed for weight loss, as fat burners, energy enhancers, as low carb diet aids, 

and to promote water loss. The following products have been recalled by the company:

Hydroxycut Regular Rapid Release Caplets; 

Hydroxycut Caffeine-Free Rapid Release Caplets; 

Hydroxycut Hardcore Liquid Caplets; 

Hydroxycut Max Liquid Caplets; 

Hydroxycut Regular Drink Packets; 

Hydroxycut Caffeine-Free Drink Packets; 

Hydroxycut Hardcore Drink Packets (Ignition Stix); 
 14 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 Hydroxycut Max Drink Packets; 

Hydroxycut Liquid Shots; 

Hydroxycut Hardcore RTDs (Ready-to-Drink); 

Hydroxycut Max Aqua Shed; 

Hydroxycut 24; 

Hydroxycut Carb Control; and 

Hydroxycut Natural.

Based on the information available to FDA, we cannot determine exactly which ingredient(s) or 

proprietary blends in Hydroxycut may be associated with liver injury, or what other factors, such 

as health condition, length of use, dosage, or use along with other dietary supplements or drugs, 

may affect the risk of using Hydroxycut.

FDA is warning consumers to immediately stop use of these products. FDA has issued a 

consumer warning advising of the potential risks associated with the use of these products and 

advising consumers to consult their health care provider if they are experiencing symptoms 

possibly associated with this product, particularly nausea, weakness or fatigue, fever, abdominal 

pain, or any change in skin color. 

We urge you to review your cases of hepatitis in order to determine if any may be related to the 

use of dietary supplements in these patients. Adverse events associated with the use of dietary 

supplements should be reported as soon as possible to FDA's MedWatch program by telephone 

(1-800-332-1088) or Internet (http://www.fda.gov/medwatch). 

Thank you for your efforts and cooperation in addressing this potentially serious public health 

issue. For additional information, see http://www.cfsan.fda.gov. 45. On May 1, 2009, the U.S. FDA warned consumers to stop using Hydroxycut products, as

the dietary supplements were felt to be linked to one death, and 23 reports of serious health problems

ranging from jaundice and elevated liver enzymes, an indicator of potential liver injury, to liver damage

requiring liver transplant. Other health problems reported include seizures, cardiovascular disorders, and rhabdomyolysis.

46. Liver injury was reported by patients at the doses of Hydroxycut recommended on the

bottle. Symptoms of serious liver disease include jaundice (yellowing of the skin or whites of the eyes),
 15 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

and brown urine. Non-specific symptoms of liver disease can include nausea, vomiting, light colored

stools, excessive fatigue, weakness, stomach or abdominal pain, itching and loss of appetite.

47. The packaging of the Hydroxycut products promotes their use to increase energy, burn calories and control appetite and boasts that they are made with clinically proven

ingredients. In addition, the packaging claims that Hydroxycut® Works Fast! The packaging further

states as follows:

Hydroxycut® is America s #1 selling weight-loss supplement. Hydroxycut really does

work fast! Utilizing sophisticated Rapid-Release Caplets, Hydroxycut is doctor

formulated+ with clinically proven ingredients top help you lose up to 4.5 times the

weight than diet and exercise alone._, Now with an improved HydroxyTea® blend, there s even more reason to love Hydroxycut®. The packaging also states: [d]on t take chances you deserve the best! Put your trust in the power of

Hydroxycut® and discover for yourself why millions of men and women all across America have used

Hydroxycut. For fast weights loss, make Hydroxycut® your #1 choice today!

48. The Hydroxycut product packaging makes much of Hyroxycut being doctor formulated

and approved. In this regard, the side of the Hydroxycut product packaging boasts that the Hydroxcut

products are Backed by Science and includes a picture of Dr. John Marshall, D.O., Resident

Physician and his statement that Hydroxycut® is a product that has ingredients proven to work. I ve

recommended it to a number of men and women and have used it myself with fantastic results. The

packaging also credits Dr. Marvin Heuer, FAAFP, Iovate s Chief Scientific Officer, with formulating

the Hydroxycut products.
 16 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

49. An example of Hydroxycut product, ingredients and directions is as follows:

50. The FDA's reasoning for the May 2009 activity and warnings over Hydroxycut products

can be found in a Health Hazard Evaluation Board document entitled "The Problem: Liver toxicity

following consumption of dietary supplements, Hydroxycut". Their conclusion was, Three lines of

evidence derived from multiple disparate sources suggest it is very likely that exposure to Hydroxycut

can cause idiosyncratic hepatoxicity The report was authored by Linda Katz, M.D., interim chief

medical officer of FDA's Center for Food Safety and Applied Nutrition.
 17 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 VI. Hydroxycut Products are Recalled

51. Iovate initiated a voluntary recall when it became aware that the U. S. FDA's assessment

of 23 reports about consumers having experienced liver-related problems, as well as a small number of

published case reports, was different from Iovate's analysis. As of May 1, 2009 the list of products that

were voluntarily recalled by Iovate included:
 18 LAW OFFICES SOMMERS SCHWARTZ, P.C. 2000 TOWN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300
 19 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

52. On May 7, 2009 the scope of the Hydroxycut recall was widened. Additional products all 

involve additional packages and sizes of products previously referenced. The UPC numbers added to

the May 1, 2009 list are as follows:

631656800265 Hydroxycut Hardcore 8 fl. oz. Grape Explosion 

631656800210 Hydroxycut Hardcore 8 fl. oz. Triple Wildberry

631656001501 Hydroxycut 280ct-3 Pak Kit *Discontinued* 631656001563 Hydroxycut 280ct-6 Pak Kit *Discontinued* 631656000658 Hydroxycut 100ct-6 month supply (7 bottles+ 4 free) Kit 631656600896 Hydroxycut 2x60ct Club Pack US Kit 631656000672 Hydroxycut 100ct-1 month supply (1 bottle+1 free) Kit *Discontinued* 631656874693 Hydroxycut 58 cap 12-pack Target US Kit *Discontinued*

631656000665 Hydroxycut 100ct-3 month supply (4 bottles+2 free) Kit *Discontinued*

631656002362 Hydroxycut Sachet Twin Pack US Kit 631656860498 Hydroxycut Instant Weight Loss Shot 12 x 2oz - Wild berry US Kit 631656660623 Hydroxycut Hardcore Shredded Stack Kit120ct

631656500585 Hydroxycut 60 Rapid Release Caplets

53. Product Defendants negligently formulated, designed, manufactured, marketed, advertised, promoted, distributed and/or sold Hydroxycut products that can potentially cause serious

health problems including, but not limited to, jaundice and liver failure.

54. Product Defendants failed to properly research the ingredients used in the Hydroxycut

products to ensure that they were safe for consumption and did not cause adverse health effects.

55. As a result of the acts and practices detailed herein and Plaintiff's and Class members

reasonable belief in the quality and safety of Hydroxycut products, and the consequent reasonable belief
 20 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

that Hydroxycut products would not have adverse health effects, Plaintiff and members of the Class

were misled into purchasing the unsafe Hydroxycut products. Hydroxycut products did not provide the

attributes and benefits Plaintiff and other members of the Class reasonably expected to receive, sought

and thought they were receiving. As a result, Plaintiff and other members of the Class bought

Hydroxycut products, which were not safe for consumption, that they would not have purchased had

Product Defendants disclosed the material facts detailed herein, which were in their exclusive possession 

and that they were obligated to disclose or should reasonably have disclosed.

56. Product Defendants failed to warn purchasers of the unreasonably dangerous

characteristics associated with Hydroxycut products, including the fact that it may cause serious liver

problems and other health problems. Product Defendants failed to institute an earlier recall of

Hydroxycut.

57. Based on the above material facts and statements, Product Defendants owed a legal duty

to Plaintiff and the Class to formulate, design, manufacture, market, advertise, distribute and sell

Hydroxycut products that were safe for human consumption or not sell such products.

58. Product Defendants breached their duty, which directly and proximately caused or

resulted in Plaintiff and other members of the Class suffering injury in fact, a loss of money or property, the personal expenditure of time and resources and/or other forms of injury and/or damage.

59. In addition, based on the duties owed to Plaintiff and other members of the Class by

Product Defendants not to expose consumers to potentially harmful products, Plaintiff and other

members of the Class are also entitled to the reasonable value of the cost of medically monitoring their

condition, as the need for medical monitoring is a reasonable consequence of suffering liver related

problems due to the consumption of Hydroxycut products and is thus necessitated as a direct result of

use, and is reasonable considering 1) the significance and extent of the consumption of Hydroxycut
 21 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

products; 2) the relative increase in the chance of onset of liver problems as a result of using Hydroxycut 

products, when compared to the chances of liver problems absent such use; 3) the seriousness of the

conditions for which the members of the Class are at risk; and 4) the clinical value of early detection.

60. Product Defendants, in the exercise of reasonable care, should have known that

Hydroxycut products potentially cause liver problems and other health problems including, but not

limited to, jaundice and liver failure. Plaintiff and members of the Class might have reasonably been

expected by Product Defendants to purchase and ingest Hydroxycut products and be adversely affected

by their defective condition.

VII. Plaintiff s Experience

61. Prior to August, 2006, Plaintiff purchased Hydroxycut Products and did so because she

had been exposed to the promotion, advertising and marketing of Hydroxycut Products as set forth in

detail herein. Entrusting Product Defendants, she relied on the reputations of the Product Defendants in

purchasing Hydroxycut Products, and was misled into thinking that Hydroxycut Products were healthy

and safe for use, which was false and misleading since the Hydroxycut Products potentially caused liver

problems and other health problems, including but not limited to, jaundice and liver failure. As a result

of the Product Defendants deceptive marketing scheme and a reliance on the purported trustworthiness

and safety of Hydroxycut Products, she was misled in the purchasing and spending money on

Hydroxycut Products. In exchange for her money, Plaintiff received something other than what was

represented, a product she did not see. As a result she was injured.

62. In August, 2006, Plaintiff was hospitalized because of flu-like symptoms. She was

lethargic, and jaundiced. Upon the examination it was determined that the Plaintiff sustained liver

damage.
 22 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

63. Plaintiff was administered high dose steroids to suppress her body s reaction to

Hydroxycut induced toxicity. Plaintiff experienced interruptions in regular sleep patterns, rapid swelling 

and huge weight gain, and experienced other adverse side-effects from the steroids.

64. She was off of work from end of August 2006 through Thanksgiving 2006. She was

required to attend many doctors appointments including a liver specialist every two weeks along with

constant blood work monitoring.

65. After the steroids, Plaintiff in March 2007 was put on Mercaptupurine to treat her liver

injury, which she continues to take currently. Her medication leaves her prone to sickness due to her

immune system being suppressed.

66. In January, 2007, Plaintiff was told that in all likelihood, her injuries were caused by use

of Hydroxycut Products. There was no other reason for her condition but for the use of Hydroxycut

products, all other causes being ruled out by medical doctors.

67. Her physicians reported this instant to the Food and Drug Administration but the FDA

has no authority over medical devices.

CLASS ACTION ALLEGATIONS

68. Pursuant to Fed. R. Civ. P. 23 (a), (b)(1) and (b)(2) and (b)(3) Plaintiff Kristen Husby

brings this action on behalf of herself and the following class defined as follows:

All individuals who purchased Hydroxycut during the relevant time period.

69. Excluded from the class are Product Defendants, authorized dealers, and their parents, subsidiaries, affiliates, employees, officers, directors and co-conspirators, any judges, justices or judicial

officers presiding over this matter and the members of their immediate families and judicial staffs.
 23 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

70. Plaintiff and the Class bring this action for money damages, declaratory judgment and

injunctive relief pursuant to subdivisions (b)(1), (b)(2) and (b)(3) of rule 23 of the Federal Rules of Civil 

Procedure.

71. Plaintiff reserves the right to modify the class description and the class period based on

the results of discovery.

72. Numerosity: Plaintiff does not know the exact number of class members because such

information is not in her possession. Due to the nature of the trade and commerce involved, however, Plaintiff believes that the total number of class members is at least in the hundreds of thousands and

members of the class are so numerous and geographically dispersed nationwide that joinder of all class

members is impracticable.

73. Common Questions of Law and Fact Predominate: Product Defendants have acted with

respect to the Class in a manner generally applicable to each class member. There is a well-defined 

community of interest in the questions of law and fact involved in the action, which affects all class

members. The questions of law or fact common to the Class predominate over any questions affecting

only individual members, including, but not limited to, the following:

a. What Product Defendants negligently failed to exercise reasonable care in 

the formulation, design, manufacture, promotion, marketing, advertising, 

packaging, labeling, distribution and/or sale of Hydroxycut?

b. Whether Product Defendants intentionally or negligently made 

misrepresentations in connection with promotion, marketing, advertising, 

packaging, labeling, distribution and/or sale of Hydroxycut?

c. Whether Product Defendants breached any warranties in connection with 

promotion, marketing, advertising, packaging, labeling, distribution and/or 

sale of Hydroxycut?

d. Whether Product Defendants were under an obligation to institute an 

earlier recall of Hydroxycut products
 24 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

e. Whether Product Defendants have been unjustly enriched at the classes 

expense in connection with promotion, marketing, advertising, packaging, 

labeling, distribution and/or sale of Hydroxycut?

f. Whether Plaintiffs were injured in connection with Product Defendants

promotion, marketing, advertising, packaging, labeling, distribution and/or 

sale of Hydroxycut?

g. Whether Plaintiff and the Class are entitled to injunctive relief?

h. Whether Plaintiff and the Class are entitled to declaratory judgment?

74. Typicality: The claims of Plaintiff are typical of the claims of the other members of the

Class in that all members of the Class have been harmed in substantially the same way by Product 

Defendants actions,

75. Adequacy of Representation: Plaintiff will fairly and adequately represent and protect the

interests of the class. Plaintiff has retained counsel with substantial experience in prosecuting complex

and class action litigation. Plaintiff and her counsel are committed to vigorously prosecuting this action

on behalf of the class, and have the financial resources to do so. 

76. Superiority of a Class Action: Plaintiff and the Cass have suffered, and will continue to

suffer, harm as a result of Product Defendants unlawful and wrongful conduct. A class action is superior 

to other available methods for the fair and efficient adjudication of the present controversy as individual

joinder of all members of the class is impractical. Even if individual class members had the resources to

pursue individual litigation, it would be unduly burdensome to the courts in which the individual

litigation would proceed. Individual litigation magnifies the delay and expense to all parties in the court

system of resolving the controversies engendered by Northstar's common course of conduct. The class

action device allows a single court to provide the benefits of unitary adjudication, judicial economy, and 

the fair and equitable handling of all class in members' claims in a single forum. The conduct of this

action as a class action conserves the resources of the parties and of the judicial system, and protects the

rights of the class member. 
 25 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

77. Adjudication of individual class members' claims with respect to the defendant would, as

a practical matter, be dispositive of the interests of other members not parties to the adjudication and

could substantially impair or impede the ability of other class members to protect their interests.

TOLLING OF APPLICABLE STATUTE OF LIMITATIONS

78. Any and all applicable statutes of limitations have been tolled by Product Defendants

affirmative and intentional acts of fraudulent conduct, concealment, and misrepresentation, alleged

above. Product Defendants engaged in a concerted effort to keep information regarding the hepatoxicity

of Hydroxycut from Plaintiff and the treating medical community, by concealing related adverse events, contradicting, silencing or attacking reputable healthcare providers and by affirmatively stating that

Hydroxycut was safe and did not carry an increased liver injury risk. Because Plaintiff could not

reasonably have discovered Defendant s wrongdoing at any time prior to the withdrawal of the drug on

May 1, 2009 Product Defendants are estopped from asserting that this action is not timely. 

COUNT I

PRODUCT LIABILITY ACTION

79. Plaintiffs repeat and re-allege all preceding paragraphs as if more fully set forth herein.

80. The Product Defendants designed, formulated, manufactured, promoted, marketed, and

advertised, packaged, labeled, and distributed Hydroxycut Products to consumers. 

81. The use of Hydroxycut products at doses recommended potentially causes serious liver

problems including, but not limited to, jaundice and liver failure.

82. The subject matter Product was not reasonably safe at the time it left the Product 

Defendants.
 26 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

83. That according to generally accepted production practices at the time said Product left the 

control of the Product Defendants, a practical and technically feasible alternative production practice

was available that would have prevented the harm including, but not limited to, not supplying it to the

general public in a context that it was given and/or changing the formula so as not to create risk of

injury.

84. The subject matter Product was not altered from the date of manufacture to the date of

use.

85. The subject matter Product was not misused by the Plaintiffs.

86. As a direct and proximate result of the Product Defendants defective condition of the

Product, Plaintiff Kristin Husby has sustained serious and permanent injuries including but not limited

to liver damage and is permanently medicated with MERCAPTUPURINE.

87. As a direct and proximate result of the Product Defendants defective condition of the

Product, Plaintiff Kristen Husby has sustained loss of earning capacity, loss of services, incurred

medical expenses, pain, suffering, loss of enjoyment of life, and mental and emotional distress.

88. As a direct and proximate result of the Product Defendants defective condition of the

Product, Plaintiff Kristen Husby will sustain in the future loss of earning capacity, loss of services, incurred medical expenses, pain, suffering, loss of enjoyment of life, and mental and emotional distress 

because said conditions are permanent.

89. Plaintiff Michael Husby has sustained a loss of services, support, and consortium, past, present and future, as a direct result of the Product Defendants negligence. COUNT II

PRODUCT LIABILITY ACTION WARNING

90. Plaintiffs repeat and re-allege all preceding paragraphs as if more fully set forth herein.
 27 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

91. The Product Defendants designed, formulated, manufactured, promoted, marketed, and

advertised, packaged, labeled, and distributed Hydroxycut Products to consumers. 92. The use of Hydroxycut products at doses recommended potentially causes serious liver

problems including, but not limited to, jaundice and liver failure.

93. That Plaintiff, Kristen Husby, was not a sophisticated user of this Product and did not

understand its chemistry, but rather relied upon false statements made by the Product Defendants as to

the safety of the Product.

94. Liver damage is not an inherent characteristic that is necessary in the formulation of diet

drugs.

95. Plaintiff, Kristen Husby, did not recognize the inherent danger in the use of the subject

Product for she was a person with ordinary knowledge to the community.

96. The Product Defendants failed to warn of the dangers of liver damage when using the

aforesaid Product.

97. As a direct and proximate result of the Product Defendants failure to adequately warn, Plaintiff, Kristen Husby, sustained serious and permanent injuries including, but not limited to, liver

damage and is permanently medicated with MERCAPTUPURINE. 98. As a direct and proximate result of the Product Defendants failure to adequately warn, Plaintiff Kristen Husby, has sustained loss of earning capacity, loss of services, incurred medical

expenses, pain, suffering, loss of enjoyment of life, and mental and emotional distress. 99. As a direct and proximate result of the Product Defendants failure to adequately warn, Plaintiff Kristen Husby will sustain in the future loss of earning capacity, loss of services, incurred

medical expenses, pain, suffering, loss of enjoyment of life, and mental and emotional distress because

said conditions are permanent.
 28 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

100. Plaintiff Michael Husby has sustained a loss of services, support, and consortium, past, present and future, as a direct result of the Product Defendants negligence. COUNT III

BREACH OF EXPRESSED WARRANTY

101. Plaintiffs repeat and re-allege all preceding paragraphs as if more fully set forth herein.

102. The Product Defendants designed, formulated, manufactured, promoted, marketed, and

advertised, packaged, labeled, and distributed Hydroxycut Products to consumers. 103. The Product Defendants also sold the subject matter Product.

104. The use of Hydroxycut products at doses recommended potentially causes serious liver

problems including, but not limited to, jaundice and liver failure. 105. The Product Defendants supplied a Product which failed to conform to its expressed

warranty of being safe to use.

106. As a direct and proximate result of the Product Defendants breach of expressed

warranty, Plaintiff Kristin Husby has sustained serious and permanent injuries including but not limited

to liver damage and is permanently medicated with MERCAPTUPURINE.

107. As a direct and proximate result of the Product Defendants breach of expressed

warranty, Plaintiff Kristen Husby has sustained loss of earning capacity, loss of services, incurred

medical expenses, pain, suffering, loss of enjoyment of life, and mental and emotional distress.

108. As a direct and proximate result of the Product Defendants breach of expressed

warranty, Plaintiff Kristen Husby will sustain in the future loss of earning capacity, loss of services, incurred medical expenses, pain, suffering, loss of enjoyment of life, and mental and emotional distress

because said conditions are permanent.

109. Plaintiff Michael Husby has sustained a loss of services, support, and consortium, past, 

present and future, as a direct result of the Product Defendants negligence.
 29 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 COUNT IV

NEGLIGENCE

110. Plaintiffs repeat and re-allege all preceding paragraphs as if more fully set forth herein.

111. The Product Defendants designed, formulated, manufactured, promoted, marketed, and

advertised, packaged, labeled, and distributed Hydroxycut Products to consumers. 

112. The use of Hydroxycut products at doses recommended potentially causes serious liver

problems including, but not limited to, jaundice and liver failure.

113. Product Defendants have a duty to exercise reasonable care in the formulation, design, manufacturing, promotion, marketing, advertising, packaging, labeling, distribution and sale of

Hydroxycut products, including a duty to ensure that Hydroxycut products are safe for use and a duty to

warn that Hydroxycut products may cause serious liver problems and other health problems, including, but not limited to, jaundice and liver failure. 

114. As set forth in detail above, Product Defendants failed to exercise reasonable care in the

formulation, design, manufacturing, promotion, marketing, advertising, packaging, labeling, distribution

and sale of Hydroxycut products by failing to ensure that Hydroxycut products were safe for use.

115. Specifically, Product Defendants were negligent in the formulation, design, manufacture, promotion, marketing, advertising, packaging, labeling, distribution and/or sale of Hydroxycut products

in that they, among other things: 

a. Failed to use reasonable care in formulating, designing and manufacturing 

Hydroxycut products so as to ensure that they were safe for use and did not cause

adverse health effects including liver problems and other health problems;

b. Failed to conduct adequate safety testing of Hydroxycut products and the

ingredients used to make Hydroxycut products; and

c. Failed to accompany Hydroxycut products with proper warnings regarding the

possible adverse health effects associated with its use including, but not limited

to, jaundice and liver failure.
 30 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

116. At the time of supply of Hydroxycut, the Product Defendants had actual knowledge that

the product was defective and that there was a substantial likelihood that the defect would cause injury

that is the basis of the action, and the Product Defendants willfully disregarded that knowledge in the

supply of Hydroxycut. 117. Despite the fact that Product Defendants knew or should have known that its Hydroxycut

products could cause serious adverse health effects, it continued to market and sell them to consumers, including Plaintiff and members of the Class, despite the reasonable possibility that Hydroxycut

products caused liver problems and other health problems including, but not limited to, jaundice and

liver failure. They failed to institute an earlier recall.

118. Product Defendants knew or should have known that Plaintiff and members of the Class

would foreseeably be put at risk of liver problems and other health problems as a result of Product 

Defendants failure to give warning of the adverse health effects associated with use of Hydroxycut

products.

119. As a direct and proximate result of the Product Defendants negligence, Plaintiff Kristin

Husby has sustained serious and permanent injuries including but not limited to liver damage and is

permanently medicated with MERCAPTUPURINE.

120. As a direct and proximate result of the Product Defendants negligence, Plaintiff Kristen

Husby has sustained loss of earning capacity, loss of services, incurred medical expenses, pain, suffering, loss of enjoyment of life, and mental and emotional distress.

121. As a direct and proximate result of the Product Defendants negligence, Plaintiff Kristen

Husby will sustain in the future loss of earning capacity, loss of services, incurred medical expenses, pain, suffering, loss of enjoyment of life, and mental and emotional distress because said conditions are

permanent.
 31 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

122. Plaintiff Michael Husby has sustained a loss of services, support, and consortium, past, present and future, as a direct result of the Product Defendants negligence. COUNT V

GROSS NEGLIGENCE

123. Plaintiffs repeat and re-allege all preceding paragraphs as if more fully set forth herein.

124. That prior to the date of incident, Product Defendants had knowledge that said

Hydroxycut Products were defective and there was a substantial likelihood that the defects would cause 

of action injury to others such as, but not limited, Plaintiffs and failed to notify others.

125. That prior to the date of incident, Product Defendants willfully disregarded knowledge of

defective conditions within the aforesaid Hydroxycut Products.

126. That Product Defendants misconduct as alleged herein, was a proximate cause of the

injuries and damages sustained by Plaintiff.

COUNT VI

RECKLESSNESS

127. Plaintiffs repeat and re-allege all preceding paragraphs as if more fully set forth herein.

128. That prior to the date of incident, Product Defendants had knowledge that said

Hydroxycut Products were defective and there was a substantial likelihood that the defect would cause

of action injury such as, but not limited that, which is the basis of this action herein involved.

129. Product Defendants willfully disregarded that knowledge.

130. That Product Defendants misconduct, as herein alleged, was a proximate cause of the

injuries and damages sustained by Plaintiff.
 32 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 COUNT VII

BREACH OF IMPLIED WARRANTY

131. Plaintiffs repeat and re-allege all preceding paragraphs as if more fully set forth herein.

132. That Product Defendants impliedly warranted that said Hydroxycut Products were free of

defect and reasonable safe for its reasonably foreseeable use.

133. Product Defendants breach its implied warranty in that said Hydroxycut Products were

defective and not reasonably fit for its reasonably foreseeable use.

134. That Product Defendants breached it implied warranty in the following particulars, including but not limited to:

a. Aforesaid Hydroxycut was defectively, manufactured and assembled;

b. Aforesaid Hydroxycut was not properly labeled;

c. Aforesaid Hydroxycut was not properly tested for safety to reduce the risk of

injury;

d. Aforesaid Hydroxycut was not supplied with adequate warnings and instructions, nor was such warnings and instructions supplemented up to the time of incident.

135. That the defective conditions of said Hydroxycut Products have heretofore alleged were a 

proximate cause of Plaintiff s injuries and damages as hereinbefore alleged. COUNT VIII

FRAUD AND MISREPRESENTATION

136. Plaintiffs repeat and re-allege all preceding paragraphs as if more fully set forth herein.

137. That Product Defendants representation that said Hydroxycut Products were safe for its

reasonably foreseeable uses amounted to fraud and misrepresentation.

138. Product Defendants, as a proximate result of said fraud and misrepresentation, Plaintiff

sustained injuries and damages as hereinbefore alleged.
 33 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 COUNT IX

MICHIGAN CONSUMERS PROTECTION ACT

139. Plaintiffs repeat and re-allege all preceding paragraphs as if more fully set forth herein.

140. That Product Defendants are in the business of trade or commerce as defined in MCL § 

445.902.

141. That Product Defendants violated MCL § 445.903 and committed unfair and deceptive

trade practices for the reasons set forth in this Complaint.

142. That as a proximate result of Product Defendants violation of the Michigan Consumers

Protection Act, Plaintiff, a person who suffered loss, sustained injuries and damages as hereinbefore

alleged, including the cost of the Hydroxycut she purchased.

WHEREFORE, Plaintiffs Kristen and Michael Husby claim judgment against Product 

Defendants, Iovate Health Sciences USA, Inc., Iovate Health Sciences International, Inc., Iovate Health

Sciences Group, Inc., Iovate Health Sciences Research, Inc., Iovate HC 2005 Formulations Ltd., Muscletech, Inc., Muscletech, Muscletech Research and Development, Inc., Jointly and Severally, as

follows:

1. Certification of the proposed class and appoint Plaintiff Kristen Husby and her

counsel as class representative and class counsel, respectively, pursuant to Fed. R. Civ. P 23;

2. Adjudge and decree that Product Defendants have engaged in the conduct alleged

herein;

3. Award Plaintiffs and class any and all damages as allowed under the law;

4. Award Plaintiffs and the Class pre and post-judgment interest as allowed by law;

5. Award counsel for Plaintiffs and the Class reasonable attorneys' fees and costs;

and
 34 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300

6. Granting such other and further relief that this Court may deem just and proper.

Respectfully submitted,

SOMMERS SCHWARTZ, P.C.

s/ Jason J. Thompson (P47184)

Robert H. Darling (P25523)

Matthew G. Curtis (P37999)

Attorneys For Plaintiffs

2000 Town Center Drive, Suite 900

Southfield, MI 48075-1100

(248) 355-0300

Plaintif s Counsel

Dated: May 20, 2009
 35 LAW

OFFICES

SO

M

MERS SCHW

ARTZ, P.C. 2000 TO

WN CENTER SUITE 900 SOUTHFIELD, MICHIGAN 48075 (248) 355-0300 DEMAND FOR JURY TRIAL

Plaintiffs hereby demand a trial by jury in the instant action pursuant to Fed. R. Civ. P 38. 

Respectfully submitted,

SOMMERS SCHWARTZ, P.C.

s/ Jason J. Thompson (P47184)

Robert H. Darling (P25523)

Matthew G. Curtis (P37999)

Attorneys For Plaintiffs

2000 Town Center Drive, Suite 900

Southfield, MI 48075-1100

(248) 355-0300

Plaintif s Counsel

Dated: May 20, 2009